SEC Comment Letter 0000000000-23-003933 to AGILE THERAPEUTICS INC (AGRX, AGXRW) (CIK 0001261249)
AGILE THERAPEUTICS INC (AGRX, AGXRW) (CIK 0001261249)
Date: April 19, 2023 · CIK: 0001261249 · Accession: 0000000000-23-003933
AI Filing Summary & Sentiment
File numbers found in text: 333-271249
Letter
United States securities and exchange commission logo April 19, 2023 Alfred Altomari Chief Executive Officer Agile Therapeutics, Inc. 500 College Road East, Suite 310 Princeton, NJ 08540 Re:Agile Therapeutics, Inc. Registration Statement on Form S-1 Filed April 14, 2023 File No. 333-271249 Dear Alfred Altomari: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jason Drory at 202-551-8342 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Bryan S. Keighery
Show Raw Text
United States securities and exchange commission logo
April 19, 2023
Alfred Altomari
Chief Executive Officer
Agile Therapeutics, Inc.
500 College Road East, Suite 310
Princeton, NJ 08540
Re:Agile Therapeutics, Inc.
Registration Statement on Form S-1
Filed April 14, 2023
File No. 333-271249
Dear Alfred Altomari:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jason Drory at 202-551-8342 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Bryan S. Keighery